RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)
Catalog #CP155
Clone:
29F.1A12ā¢-CP155
Reactivities:
Mouse
Isotype:
Mouse IgG2a
(switched from rat IgG2a)
(switched from rat IgG2a)
Product Details
The 29F.1A12ā¢-CP155 monoclonal antibody is a recombinant chimeric version of the original 29F.1A12ā¢ antibody. The variable domain sequences are identical to the original 29F.1A12ā¢ but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. The 29F.1A12ā¢-CP155 antibody contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous FcĪ³ receptors. 29F.1A12ā¢-CP155 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1ās structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.Specifications
| Isotype | Mouse IgG2a,Ā Īŗ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | LALA-PG |
| Immunogen | Recombinant PD-1-Ig fusion protein |
| Reported Applications |
in vivo blocking of PD-1/PD-L signaling* in vitro PD-1 neutralization* Immunohistochemistry (frozen)* Immunofluorescence* Western blot* Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
| Sterility | 0.2 Āµm filtration |
| Production | Purified from CHO cell supernatant in an animal free facility |
| Purification | Protein G |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Additional Formats
Recommended Products
-
Recommended Isotype Control(s)
RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer
